

8. **Frothingham R**, Meeker-O'Connell WA. Genetic diversity in the *Mycobacterium tuberculosis* complex based on variable numbers of DNA repeats. *Microbiology* 1998;**144**:1189–96.
9. **Supply P**, Lesjean E, Savine E, *et al*. Automated high-throughput genotyping for study of global epidemiology of *Mycobacterium tuberculosis* based on mycobacterial interspersed repetitive units. *J Clin Microbiol* 2001;**39**:3563–71.
10. **Hawkey PM**, Smith EG, Evans JT. Mycobacterial interspersed repetitive unit typing of *Mycobacterium tuberculosis* compared to IS6110 based restriction fragment length polymorphism analysis for investigation of apparently clustered cases of tuberculosis. *J Clin Microbiol* 2003;**41**:3514–20.
11. **Oelemann MC**, Diel R, Vatin V, *et al*. Assessment of an optimized mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. *J Clin Microbiol* 2007;**45**:691–7.
12. **Evans JT**, Hawkey PM, Smith EG, *et al*. Automated high-throughput mycobacterial interspersed repetitive unit typing of *Mycobacterium tuberculosis* strains by a combination of PCR and nondenaturing high-performance liquid chromatography. *J Clin Microbiol* 2004;**42**:4175–80.
13. *UK Mycobacterium tuberculosis Strain Typing Database*. <http://www.hpa-bionum.org.uk/TBtyping/home.php> (accessed Mar 2010).
14. *Tuberculosis in the UK: annual report on TB surveillance in the United Kingdom 2010*. London: Health Protection Agency Centre for Infections, 2010.
15. **Maguire H**, Dale J, McHugh T, *et al*. Molecular epidemiology of tuberculosis in London 1995–7 showing low rate of active transmission. *Thorax* 2002;**57**:617–22.
16. **Hayward AC**, Goss S, Drobniewski F, *et al*. The molecular epidemiology of tuberculosis in Inner London. *Epidemiol Infect* 2002;**128**:175–84.
17. **Allix-Beguec C**, Fauville-Dufaux M, Supply P. Three-year population based evaluation of standardized mycobacterial interspersed repetitive-unit-variable number tandem-repeat typing of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2008;**46**:1396–406.
18. **López-Calleja AI**, Lezcano MA, Vitoria MA, *et al*. Genotyping of *Mycobacterium tuberculosis* over two periods: a changing scenario for tuberculosis transmission. *Int J Tuberc Lung Dis* 2007;**11**:1080–6.
19. **Perdigão J**, Macedo R, João I, *et al*. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. *Microb Drug Resist* 2008;**14**:133–43.
20. **De Vries G**, van Hest RA, Burdo CC, *et al*. A *Mycobacterium tuberculosis* cluster demonstrating the use of genotyping in urban tuberculosis control. *BMC Infect Dis* 2009;**9**:151.

## Journal club

### Endobronchial valves for advanced emphysema

In this multicentre randomised trial from USA, the safety and efficacy of unilobar endobronchial valve therapy in patients with heterogeneous emphysema was compared with usual care.

In terms of effectiveness, the co-primary outcomes were percentage change in FEV<sub>1</sub> and distance on the 6 min walk test. In terms of safety, the primary outcome was the difference in complication rate, using a composite of six major complications including death, empyema, massive haemoptysis, pneumonia distal to the valves and pneumothorax or air leak of more than 7 days duration.

Patients with endobronchial valves showed modest improvements in FEV<sub>1</sub> and 6 min walk test distance, but at the cost of more pneumonia, including episodes requiring hospitalisation, chronic obstructive pulmonary disease exacerbations and haemoptysis. Follow-up was for 12 months with most complications occurring in the 6 months after valve insertion. There were also modest improvements in secondary end points including quality of life, dyspnoea and supplemental oxygen use.

Of note, there were substantial missing data for the primary efficacy end points, but similar rates were observed in control and intervention groups. There was a higher drop out rate in the control group. It was noted that patients in the high heterogeneity subgroup had greater improvements in FEV<sub>1</sub> and distance on the 6 min walk test. The study was not powered to compare subgroups but this suggests that, similar to lung volume reduction surgery, appropriate patient selection is key to good outcomes.

Therapeutic interventions for advanced emphysema are limited. The role of endobronchial valve therapy remains unclear. There are no direct comparisons with lung volume reduction surgery, but benefits are likely to include lower complication rates, and perhaps mortality. Careful patient selection using expert analysis of high-resolution CT is vital and likely to be an area of future research.

► **Scuirba FC**, Ernst A, Herth FJF, *et al*. A randomized study of endobronchial valves for advanced emphysema. *N Engl J Med* 2010;**363**:1233–44.

#### Laura-Jane E Smith

**Correspondence to** Dr Laura-Jane E Smith, ST2, University College Hospital NHS Trust, Department of Thoracic Medicine, 250 Euston Road, London NW1 2PG, UK; [smith.laurajane@gmail.com](mailto:smith.laurajane@gmail.com)

Published Online First 10 February 2011

*Thorax* 2011;**66**:713. doi:10.1136/thx.2011.159442